Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
By MedImaging International staff writers Posted on 22 Jan 2024 |
Medullary thyroid cancer (MTC) represents about 3% of all thyroid cancer cases and is notably rare. It arises from different cells compared to other thyroid cancers, necessitating distinct imaging and treatment approaches. The overexpression of the cholecystokinin-2 receptor (CCK-2R) on most MTC cells has led to the development of various compounds targeting this receptor. However, many of these compounds suffer from low metabolic stability, which hampers their effectiveness in radioligand therapy. Now, a newly developed PET imaging agent has shown promise in both preclinical and clinical studies for identifying MTC, suggesting its potential as a theranostic tool in clinical settings.
In a study conducted by researchers at Stanford University (Stanford, CA, USA), three compounds—DOTA-CCK-66, DOTA-CCK 66.2, and DOTA-MGS5—were each labeled with different isotopes: 64Cu, 67Ga, and 177Lu. The team evaluated the CCK-2R affinity of these radiolabeled compounds on MTC cells. All compounds displayed high affinity, but DOTA-CCK-66 was selected for further study due to its superior in vitro properties, leading to the exclusion of DOTA-CCK-66.2 from subsequent analyses.
Following this, the researchers carried out in vivo stability, biodistribution, imaging, and competition studies using mice with CCK-2R-expressing tumors. Based on its comprehensive in vitro and in vivo performance, 68Ga-DOTA-CCK-66 was chosen for a proof-of-concept PET/CT application. Subsequently, two MTC patients underwent 68Ga-DOTA-CCK-66 PET/CT scans. The scans revealed that the compound was well tolerated by the patients, exhibited favorable biodistribution, and demonstrated high activity accumulation in the tumors.
“Due to increased in vivo stability, our compound reveals favorable tumor uptake as well as an improved activity clearance from off-target tissues,” said Constantin Lapa, MD, director of nuclear medicine at University Hospital Augsburg. “This could result in enhanced lesion detection in PET imaging and additionally enable targeted MTC radioligand therapy.”
Related Links:
Stanford University
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure